


Claims

- [Claim 1] A compound of the following Formula 1, or a pharmaceutically acceptable salt or isomer thereof:
[Formula 1]
- 
- wherein R1 is C₂-C₅ alkyl.
- [Claim 2] The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 1, wherein R1 is C₂-C₄ alkyl.
- [Claim 3] The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 2, wherein R1 is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
- [Claim 4] The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 2, wherein the compound is selected from the following group:
N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)isobutyramide;
N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)propionamide; and
N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)pivalamide.
- [Claim 5] The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid.
- [Claim 6] The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 5, wherein the pharmaceutically acceptable salt is

- hydrochloride.
- [Claim 7] A melanocortin receptor agonistic pharmaceutical composition comprising the compound of Formula 1, or a pharmaceutically acceptable salt or isomer thereof as defined in any one of Claims 1 to 6 as an active ingredient, together with a pharmaceutically acceptable carrier.
- [Claim 8] The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for the prevention or treatment of obesity.
- [Claim 9] The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for the prevention or treatment of diabetes.
- [Claim 10] The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for the prevention or treatment of inflammation.
- [Claim 11] The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for the prevention or treatment of erectile dysfunction.
- [Claim 12] Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of obesity.
- [Claim 13] Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of diabetes.
- [Claim 14] Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of inflammation.
- [Claim 15] Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of erectile dysfunction.
- [Claim 16] A method of preventing or treating obesity in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 to the subject.
- [Claim 17] A method of preventing or treating diabetes in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 to the subject.
- [Claim 18] A method of preventing or treating inflammation in a subject in need thereof, comprising administering the melanocortin receptor agonistic

[Claim 19] pharmaceutical composition according to Claim 7 to the subject.
A method of preventing or treating erectile dysfunction in a subject in
need thereof, comprising administering the melanocortin receptor
agonistic pharmaceutical composition according to Claim 7 to the
subject.